These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17762855)

  • 1. Development of therapeutic siRNAs for pachyonychia congenita.
    Smith FJ; Hickerson RP; Sayers JM; Reeves RE; Contag CH; Leake D; Kaspar RL; McLean WH
    J Invest Dermatol; 2008 Jan; 128(1):50-8. PubMed ID: 17762855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-nucleotide-specific siRNA targeting in a dominant-negative skin model.
    Hickerson RP; Smith FJ; Reeves RE; Contag CH; Leake D; Leachman SA; Milstone LM; McLean WH; Kaspar RL
    J Invest Dermatol; 2008 Mar; 128(3):594-605. PubMed ID: 17914454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients.
    Hickerson RP; Leake D; Pho LN; Leachman SA; Kaspar RL
    J Dermatol Sci; 2009 Nov; 56(2):82-8. PubMed ID: 19699613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic interference: a step closer for pachyonychia congenita?
    Rugg EL
    J Invest Dermatol; 2008 Jan; 128(1):7-8. PubMed ID: 18071332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SiRNA-mediated selective inhibition of mutant keratin mRNAs responsible for the skin disorder pachyonychia congenita.
    Hickerson RP; Smith FJ; McLean WH; Landthaler M; Leube RE; Kaspar RL
    Ann N Y Acad Sci; 2006 Oct; 1082():56-61. PubMed ID: 17145926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of self-delivery siRNAs to inhibit gene expression in an organotypic pachyonychia congenita model.
    Hickerson RP; Flores MA; Leake D; Lara MF; Contag CH; Leachman SA; Kaspar RL
    J Invest Dermatol; 2011 May; 131(5):1037-44. PubMed ID: 21248764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of quantitative molecular clinical end points for siRNA clinical trials.
    Hickerson RP; Leachman SA; Pho LN; Gonzalez-Gonzalez E; Smith FJ; McLean WH; Contag CH; Leake D; Milstone LM; Kaspar RL
    J Invest Dermatol; 2011 May; 131(5):1029-36. PubMed ID: 21191405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita.
    Zhao Y; Gartner U; Smith FJ; McLean WH
    J Invest Dermatol; 2011 May; 131(5):1045-52. PubMed ID: 21390048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling in pachyonychia congenita skin.
    Cao YA; Hickerson RP; Seegmiller BL; Grapov D; Gross MM; Bessette MR; Phinney BS; Flores MA; Speaker TJ; Vermeulen A; Bravo AA; Bruckner AL; Milstone LM; Schwartz ME; Rice RH; Kaspar RL
    J Dermatol Sci; 2015 Mar; 77(3):156-65. PubMed ID: 25656049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Invasive Intravital Imaging of siRNA-Mediated Mutant Keratin Gene Repression in Skin.
    Hickerson RP; Speaker TJ; Lara MF; González-González E; Flores MA; Contag CH; Kaspar RL
    Mol Imaging Biol; 2016 Feb; 18(1):34-42. PubMed ID: 26169581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A spectrum of mutations in keratins K6a, K16 and K17 causing pachyonychia congenita.
    Liao H; Sayers JM; Wilson NJ; Irvine AD; Mellerio JE; Baselga E; Bayliss SJ; Uliana V; Fimiani M; Lane EB; McLean WH; Leachman SA; Smith FJ
    J Dermatol Sci; 2007 Dec; 48(3):199-205. PubMed ID: 17719747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel missense mutation L468Q of keratin 6a in pachyonychia congenita type 1.
    Zhou HL; Yang S; Gao M; Zhao XY; Zhu YG; Li W; Ren YQ; Liang YH; Du WH; Zhang XJ
    J Eur Acad Dermatol Venereol; 2007 Mar; 21(3):351-5. PubMed ID: 17309457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotype and genotype features of Vietnamese children with pachyonychia congenita.
    Chu HT; Dinh Duong TA; Le DH; Le TV; Nguyen BB; Dang CV; Vu QV
    Pediatr Neonatol; 2023 Jul; 64(4):405-410. PubMed ID: 36658016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita.
    Leachman SA; Hickerson RP; Hull PR; Smith FJ; Milstone LM; Lane EB; Bale SJ; Roop DR; McLean WH; Kaspar RL
    J Dermatol Sci; 2008 Sep; 51(3):151-7. PubMed ID: 18495438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hedgehog signaling, keratin 6 induction, and sebaceous gland morphogenesis: implications for pachyonychia congenita and related conditions.
    Gu LH; Coulombe PA
    Am J Pathol; 2008 Sep; 173(3):752-61. PubMed ID: 18688029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The phenotypic and molecular genetic features of pachyonychia congenita.
    McLean WH; Hansen CD; Eliason MJ; Smith FJ
    J Invest Dermatol; 2011 May; 131(5):1015-7. PubMed ID: 21430705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype‒Structurotype‒Phenotype Correlations in Patients with Pachyonychia Congenita.
    Wu TT; Eldirany SA; Bunick CG; Teng JMC
    J Invest Dermatol; 2021 Dec; 141(12):2876-2884.e4. PubMed ID: 34116063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The 521 T--> C mutation in the keratin 6A gene in a pedigree with pachyonychia congenita type I].
    Yang L; Li M; Lai M; Ni J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):66-8. PubMed ID: 20140871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pachyonychia congenita: a case report.
    Kohli N
    Cutis; 2009 Nov; 84(5):269-71. PubMed ID: 20099620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pachyonychia congenita associated with median rhomboid glossitis.
    Karen JK; Schaffer JV
    Dermatol Online J; 2007 Jan; 13(1):21. PubMed ID: 17511954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.